ABBV knows the Nex-Gen capabilities already. If the data is good, with this next HCV compound may bring $500M+ annual royalties stream in just few years to ENTA at its present Market Cap of just $850M.
Furthermore, the new ENTA owner will be definitely not so nice to ABBV as the present management is. Someone with plenty tax losses will greatly benefit from this royalty stream.
News 
Market Data 
Discover 
